Damora Therapeutics DMRA
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$4.67M (6 inflow days, 14 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 47.1% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 7.68% to 7.60% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BlackRock | Mutual Fund | 2026/Q3 | +352,505 | 5.7% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +344,895 | 0.9% |
| FMR | Mutual Fund | 2026/Q3 | +316,077 | 15.4% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +242,553 | 1.8% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +237,922 | 1.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +235,397 | 2.9% |
| BMO Asset Management | Mutual Fund | 2026/Q3 | +205,519 | 0.3% |
| Jennison Associates LLC | Mutual Fund | 2026/Q3 | +153,109 | 0.2% |
| Jennifer Jarrett | Individual/Insider | 2026/Q3 | +512,500 | 0.8% |
| Jennison Associates LLC | Mutual Fund | 2026/Q3 | +153,109 | 0.2% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +106,377 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +2,939,631 | 5.1% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +2,009,849 | 3.3% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,361,578 | 2.5% |
| Blackstone Alternative Investment Advisors LLC | Mutual Fund | 2026/Q3 | +1,002,971 | 1.6% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 24 Sep 2026 | Jennifer Jarrett | Chief Executive Officer | Open Market Acquisition | +12,500 | $20.23 | 12,500 |
| 11 Aug 2026 | Andrew Cheng | Director | Other Derivative Acquisition | +30,350 | $31.00 | 30,350 |
| 4 Aug 2026 | Lori Firmani | Former Chief Financial Officer | Intent to Sell (Form 144) | -1,800 | $31.10 | – |
| 5 Jul 2026 | Garrett Winslow | Senior Vice President | Derivative Exercise and Sale | -245 | $29.98 | 2,289 |
| 2 Jul 2026 | Garrett Winslow | Senior Vice President | Derivative Exercise and Retained | +435 | – | 2,289 |
| 21 Jun 2026 | Lori Firmani | Former Chief Financial Officer | Intent to Sell (Form 144) | -7,615 | $25.36 | – |
| 30 Apr 2026 | Brian Burkavage | Senior VP of Finance, Principal Financial & Accounting Officer | Initial Statement of Beneficial | +0 | – | 312,535 |
| 29 Mar 2026 | Jennifer Jarrett | Chief Executive Officer | Other Acquisition | +500,000 | – | 500,000 |
| 29 Mar 2026 | Jennifer Jarrett | Chief Executive Officer | Other Derivative Acquisition | +1,500,000 | $25.50 | 1,500,000 |
| 22 Mar 2026 | Michael Landsittel | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 | 37,313 |
| 22 Mar 2026 | Christopher Cain | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 | 37,313 |
| 22 Mar 2026 | Garrett Winslow | Senior Vice President | Other Derivative Acquisition | +250,000 | $23.05 | 250,000 |
| 22 Mar 2026 | Cameron Turtle | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 | 37,313 |
| 22 Mar 2026 | Peter Harwin | Independent Chairperson | Other Derivative Acquisition | +37,313 | $23.05 | 37,313 |
| 22 Mar 2026 | Julianne Bruno | Independent Director | Other Derivative Acquisition | +37,313 | $23.05 | 37,313 |
| 8 Feb 2026 | Fairmount Funds Management LLC | Derivative Exercise and Retained | +8,713,000 | – | 8,713,000 | |
| 8 Feb 2026 | Julianne Bruno | Independent Director | Derivative Exercise and Retained | +129,000 | – | 137,032 |
| 4 Jan 2026 | Becker Hewes | Chief Medical Officer | Other Acquisition | +264,629 | – | 264,629 |
| 4 Jan 2026 | Becker Hewes | Chief Medical Officer | Other Derivative Acquisition | +528,603 | $21.82 | 528,603 |
| 4 Jan 2026 | Sherwin Sattarzadeh | Chief Operating Officer | Other Acquisition | +190,376 | – | 190,376 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 4,689,717 | 7.6% | 10.7 |
| 15 Oct 2026 | 5,152,194 | 8.3% | 11.2 |
| 30 Sep 2026 | 4,733,297 | 7.7% | 4.8 |
| 15 Sep 2026 | 4,732,463 | 7.7% | 8.6 |
| 31 Aug 2026 | 4,131,367 | 6.7% | 13.3 |
| 14 Aug 2026 | 4,739,939 | 7.7% | 13.6 |
No comments yet — be the first to weigh in on DMRA.
Sign in to join the discussion.